Epoetin alfa ( DrugBank: Epoetin alfa )


3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
13多発性硬化症/視神経脊髄炎1
18脊髄小脳変性症(多系統萎縮症を除く。)2
46悪性関節リウマチ2

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,342 薬物数 : 2,380 - (DrugBank : 407) / 標的遺伝子数 : 266 - 標的パスウェイ数 : 240
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-005592-14-DE
(EUCTR)
27/07/200612/05/2006Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PROTECT) - Vision ProtectDouble blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PROTECT) - Vision Protect Multiple sclerosis (MS) is a chronic disease of the central nervous system.Optic neuritis represents one of the most common and frequently the first clinical manifestation of MS. Optic neuritis is mainly characterized by a subacute loss of vision.Trade Name: Erypo/Erypo FS
Product Name: Erypo/Erypo FS
INN or Proposed INN: Epoetin alfa
Other descriptive name: Epo
Trade Name: Urbason solubile forte 1000mg
Product Name: Methylprednisolone
INN or Proposed INN: Methylprednisolon-21-hydrogensuccinat, Natriumsalz
IFSgGmbH, Institute for clinical researchNULLNot RecruitingFemale: yes
Male: yes
Germany

18. 脊髄小脳変性症(多系統萎縮症を除く。)


臨床試験数 : 71 薬物数 : 101 - (DrugBank : 30) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01493973
(ClinicalTrials.gov)
January 201315/12/2011Efficacy Study of Epoetin Alfa in Friedreich AtaxiaA Double-blind, Randomized, Placebo-controlled, Clinical Trial to Test the Efficacy of Epoetin Alfa on Physical Performance of Friedreich Ataxia Patients.Friedreich AtaxiaDrug: Epoetin alfa;Drug: PlaceboFederico II UniversityFriedreich's Ataxia Research Alliance;Associazione Italiana per la lotta alle Sindromi Atassiche (AISA)Completed12 YearsN/ABoth56Phase 2Italy
2EUCTR2011-006156-37-IT
(EUCTR)
10/07/201226/07/2012Erythropoieitn in Friedreich AtaxiaA double-blind, randomized, placebo-controlled, clinical trial to test the efficacy of Epoetin alfa on physical performance of Friedreich Ataxia patients. - FRIEMAX FRIEDREICH ATAXIA
MedDRA version: 14.1;Level: PT;Classification code 10008025;Term: Cerebellar ataxia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: EPREX*1SIR 40000UI/ML 1ML
INN or Proposed INN: EPOETIN ALFA
Trade Name: EPREX*1SIR 10000UI 1ML
INN or Proposed INN: EPOETIN ALFA
Trade Name: BINOCRIT*1SIR 40000UI/1ML
INN or Proposed INN: EPOETIN ALFA
UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO IINULLNot RecruitingFemale: yes
Male: yes
Phase 2Italy

46. 悪性関節リウマチ


臨床試験数 : 4,325 薬物数 : 2,681 - (DrugBank : 417) / 標的遺伝子数 : 185 - 標的パスウェイ数 : 223
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00123149
(ClinicalTrials.gov)
January 200519/7/2005Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid ArthritisAn Open-Label (OL) Extension Study to Assess Safety of PROCRIT (Epoetin Alfa) in Patients With Anemia of Chronic Disease (ACD) Due to Rheumatoid Arthritis (RA)Anemia;Rheumatoid ArthritisDrug: Epoetin alfaOrtho Biotech Products, L.P.NULLWithdrawn18 Years99 YearsBoth0Phase 2NULL
2NCT00236678
(ClinicalTrials.gov)
July 20047/10/2005Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRITA Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With Anemia of Chronic Disease (ACD) Due to Rheumatoid Arthritis Receiving PROCRIT? (Epoetin Alfa)Anemia;Rheumatoid ArthritisDrug: Epoetin alfaJohnson & Johnson Pharmaceutical Research & Development, L.L.C.Ortho Biotech Products, L.P.Terminated18 YearsN/ABoth29Phase 2NULL